Novo Nordisk's GLP-1 dominance fades as Eli Lilly closes the gap in 2026

Novo Nordisk remains a key player in the GLP-1 drug market, despite recent challenges. The company's shares have underperformed compared to broader stock market trends over the past two years. Yet, its strong position in diabetes and weight-loss treatments continues to attract investor interest. The company's dominance in the GLP-1 sector has weakened in recent years. Its market share dropped from around 70% in 2023 to roughly 50% by early 2026. Meanwhile, rival Eli Lilly expanded its footprint, climbing from about 25% to 45% over the same period. This shift comes as Lilly's drugs, Mounjaro and Zepbound, compete directly with Novo Nordisk's Ozempic and Wegovy. The company's flagship product, semaglutide, remains one of the top-selling GLP-1 therapies. Brands like Wegovy, Ozempic, and Rybelsus still generate significant revenue. However, analysts project a year-over-year decline in sales for 2026. Novo Nordisk is not without opportunities. Several pipeline candidates in the GLP-1 niche are nearing approval. The company also holds substantial cash reserves for potential licensing deals and acquisitions. Its expertise in developing GLP-1 drugs keeps it well-placed in a stock market expected to grow substantially over the next decade. Yet, even with strong execution, achieving a 25.89% compound annual growth rate over the next ten years appears unlikely. The firm's dividend, however, could still provide steady returns for long-term investors. Novo Nordisk faces increasing competition from Eli Lilly, with its market share shrinking. The company's deep pipeline and financial strength offer a solid foundation for future growth. For now, its dividend and leadership in diabetes and weight-loss treatments remain key factors for investors.